News — AI supercycle headlines

Benzinga3h agobearish

SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline. CEO Angelos Stergiou said the company continued advancing its clinical programs during the quarter while preparing for the anticipated data readout from its pivotal Phase 3 REGAL study. SELLAS will release the upcoming data after the study reaches its pre-specified 80th event threshold — a major milestone for the

SLS

Insider Monkey29d agobearish

SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]

Insider Monkey46d agobearish

SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]

SLS

Simply Wall St.52d agobearish

Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run

Assessing recent moves in SELLAS Life Sciences Group (SLS) SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 months and year that stand out against its mixed multi year track record. Over the past month the stock shows a gain, alongside a much stronger move in the past 3 months and a very large 1 year total return, while 5 year performance remains negative. That mix often prompts investors to revisit the story behind the...

SLS

24/7 Wall St.54d agobearish

SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

SLS

Simply Wall St.64d agobearish

SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s Changed

In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...

SLS

Simply Wall St.67d agobearish

Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial Updates

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...

SLS